Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab
Open Access
- 1 January 2008
- journal article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 10 (5), R105
- https://doi.org/10.1186/ar2497
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker resultsAnnals Of The Rheumatic Diseases, 2007
- Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullinationArthritis & Rheumatism, 2005
- BLyS and APRIL in rheumatoid arthritisJCI Insight, 2005
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritisArthritis & Rheumatism, 2003
- Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritisArthritis & Rheumatism, 2003
- Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletionAnnals Of The Rheumatic Diseases, 2002
- Immunoglobulin G3 subclass production by rheumatoid synovial tissue cultures.JCI Insight, 1982
- In vitro synthesis of immunoglobulin by rheumatoid synovial membraneJCI Insight, 1968